Navigation Links
YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
Date:11/11/2009

------------------------------------------ ------------------------------------------------------------------------- Weighted average number of common shares outstanding 55,844,505 55,835,356 Excludes common shares held in escrow for contingent additional payment related to the acquisition of Delex Therapeutics Inc. 2,380,953 2,380,953 ------------------------------------------------------------------------- ------------------------------------------------------------------------- YM BIOSCIENCES INC. Interim Consolidated Statements of Cash Flows (Expressed in Canadian dollars, unless otherwise noted) ------------------------------------------------------------------------- Three months ended September 30, 2009 2008 ------------------------------------------------------------------------- (Unaudited) Cash provided by (used in): Operating activities: Loss for the period $ (3,502,788) $ (3,156,212) Items not involving cash: Amortization of property and equipment 16,252 18,631 Amortization of intangible assets 265,136 265,136 Loss on short-term deposits 2,218 140,559 Stock-based compensation 396,644 190,333 Change in non-cash operating working capital: Accounts receivable and prepaid expenses 246,035 (109,840) Accounts payable, accrued liabilities and deferred revenue (4,850) (683,008) -----------------------------------------------------------
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Whitehouse Laboratories is excited to ... with PTI Inspection Systems that will enable ... the art leak testing method development and validation programs ... available. As part of this agreement, Whitehouse Labs has ... Detection Instrument developed and manufactured by PTI. The ...
(Date:8/27/2014)... 27, 2014 Rhythm, a biopharmaceutical company developing ... that result in metabolic disorders, announced today that it ... the U.S. Securities and Exchange Commission (SEC) relating to ... common stock. The number of shares to be offered ... yet been determined. Citigroup and Cowen and ...
(Date:8/27/2014)... 27, 2014   MSC , a healthcare performance ... announced the appointment of Mary Beth Loesch ... years of experience preparing companies for rapid growth and ... Vice President of Corporate Development and Healthcare. In that ... , as well as corporate strategy and marketing. Previously, ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new ... Global Chelating Agents Market 2014-2018 ... Chelating Agent A chelating agent is a chemical ... ions, thereby forming a metal-ion complex. It reduces ... chemical processes, formulations, and the environment by chelating ...
Breaking Biology Technology:Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2MSC names Mary Beth Loesch President and CEO 2Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4
... Virtify, Inc., a leading provider of structured content ... the appointment of Craig Smith as the company,s new ... the enterprise software industry, Smith has established a strong ... new markets and building outstanding sales organizations. ...
... Neuralstem, Inc. (Amex: CUR ) announced ... ending litigation between the parties.  The confidential settlement agreement ... Neuralstem, Inc. v. ReNeuron, Ltd. , Case No. ... United States District Court for the Central District of ...
... WASHINGTON, Jan. 27, 2011 Following are the comments ... (D-Ore.) on USDA,s announcement Thursday that the agency will ... engineered (GE) alfalfa, a key commodity in dairy farming, ... GE crop approved for widespread planting. Leahy and DeFazio ...
Cached Biology Technology:Content Management and Life Sciences Software Veteran Joins Virtify as Vice President of Worldwide Sales 2Content Management and Life Sciences Software Veteran Joins Virtify as Vice President of Worldwide Sales 3Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd. 2USDA's Decision Thursday on Genetically Engineered Alfalfa -- Leahy and DeFazio Warn About USDA Decision Lifting All Protections for Organic and Conventional Farmers 2
(Date:8/28/2014)... 2014  Privacy Advocate and Senior Staff Attorney at ... joins the lineup of biometric and mobile commerce experts ... Executive Summit in Tampa, Florida ... speakers include Steven Rahman, Director, Technology and Strategy at Samsung, ... The theme of this year,s event is Mobility at ...
(Date:8/28/2014)... 28, 2014A new method for measuring and imaging how ... and researchers better understand how drug abuse affects the ... tissue engineering, and lead to better treatment options for ... team of researchers from Stony Brook University in New ... was published today in The Optical Society,s (OSA) open-access ...
(Date:8/28/2014)... could pose a significant health risk to people with asthma ... of Allergy and Clinical Immunology . , By critically reviewing ... research has found that the presence of several types of ... well as increasing the likelihood of developing the condition. , ... University of Exeter Medical School and is the first time ...
Breaking Biology News(10 mins):Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Indoor mold poses health risk to asthma sufferers 2
... the open state of a membrane-protein's ion channel have ... to obtain a detailed picture of the effect of ... residues for protons. , The findings, reported in the ... welcome news for chemists and biophysicists, both experimentalists and ...
... Researchers at the Oregon National Primate Research Center at ... key gene that appears to control how stem cells ... significant implications for the study of Parkinson's disease, brain ... that might be combated by replacing lost or damaged ...
... Department of Chemistry have developed a gel that could ... side-effects of radiotherapy. , PhD students Andrew Wilson and ... have developed the gel which will help doctors to ... has secured £30,000 under the Bioscience Yorkshire Enterprise Fellowship ...
Cached Biology News:New technique helps researchers determine amino-acid charge 2OHSU discovery sheds light into how stem cells become brain cells 2Young scientists turn to gel to ease side-effects of cancer treatment 2
1 unit is sufficient for 1 caspase activity assay....
Applications: (+) Immunocytochemistry and immunohistochemistry...
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Biology Products: